Drug Profile
Research programme: small molecule therapeutics - Algiax Pharmaceuticals
Alternative Names: AP-19; AP-3; AP-4; AP-61; AP-778; AP-8; ThAc derivatives; Thioacrylamide derivativesLatest Information Update: 20 Jun 2023
Price :
$50
*
At a glance
- Originator Algiax Pharmaceuticals
- Class Imidazoles; Small molecules; Triazines
- Mechanism of Action GABA A receptor modulators; Type 4 cyclic nucleotide phosphodiesterase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus
- No development reported Cognition disorders; Neuropathic pain
Most Recent Events
- 20 Jun 2023 Preclinical development for Diabetes is still ongoing in Germany (Algiax Pharmaceuticals pipeline, June 2023)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Germany
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cognition-disorders in Germany